Our Three Principles of Product Development

Strong Science
All IMH products are grounded in strong science. They reflect a high degree of knowledge about the medical conditions that need to be addressed. All products are based on sound clinical research principles to support their efficacy, safety and tolerability in the dietary management of gastrointestinal conditions.

Well-Studied Ingredients
Ingredients are Generally Recognized as Safe (GRAS), self affirmed GRAS, or are acceptable food additives. Ingredients benefit from the company’s rigorous quality standards that often exceed established standards.

Smart Delivery
And perhaps most importantly... IMH strives to deliver ingredients in the area of the digestive tract where they are needed most. One of these delivery technologies is the patented SST™ (Site Specific Targeting) technology.

IM HealthScience® aspires to become the leading Medical Foods innovator. Its present focus is on underserved patients with gastrointestinal conditions. Areas of high unmet medical need include IBS, Functional Dyspepsia, Diverticulosis, Ulcerative Colitis, and Crohn’s Disease. These are priority areas for IMH research.

IMH launched IBgard® nationally in 2015 for patients with IBS. IBgard has been very well received by patients who have given their feedback to their physicians. In the meantime, the medical consensus around IBgard and its utility in IBS has been further strengthened by the emergence of three important studies, IBSREST™1, IBSRRET™,2 and IBSACT™3 presented at DDW, AGA, and ACG meetings. This medical consensus has been further confirmed by the formal approval of IBgard by Health Canada in 2015.

IMH launched FDgard® nationally in May of 2016 for patients with Functional Dyspepsia (FD). Also known as non-ulcer dyspepsia, or recurring indigestion*, the main symptoms of FD are upper belly pain or discomfort, early fullness with meals, nausea, bloating and belching. Currently, there are no other over-the-counter-products, prescription products or medical foods for patients with Functional Dyspepsia. IMH developed FDgard® using its SST® (Site-Specific Targeting) technology to deliver a well understood and clinically studied combination of ingredients.

IM HealthScience is also proud to be marketing two validated dietary supplements, both of which may often be used in adjacent settings to IBgard and FDgard.

The first of these dietary supplements is Fiber Choice®. Fiber Choice contains inulin, a natural fiber found in many fruits and vegetables. Besides helping support regularity, Fiber Choice has important prebiotic properties. The science of the microbiome is rapidly growing (see Figure 1),4 and Fiber Choice is well positioned to benefit from this.

Fig. 1

Fiber Choice is also available as Fiber Choice Flavor Drops™. This preparation contains FDA approved dietary fiber, soluble corn fiber. Fiber Choice Flavor Drops is a water enhancer that is appropriate for an active lifestyle that can benefit from "fiber on the go."

The second dietary supplement marketed by IMH is REMfresh®, a patented 7-hour melatonin delivery system for helping consumers fall asleep and stay asleep. REMfresh is the #1 sleep specialist recommended modified release melatonin supplement.* Sleep is an important challenge among patients with IBS, FD and other digestive conditions.

Medical practitioners welcome the opportunity to have a selection of four IMH brands to recommend from: IBgard, FDgard, Fiber Choice, and REMfresh.

1 Cash BD, Epstein MS, Shah SM. A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms. Dig Dis Sci. 2016;61(2):560-571. doi:10.1007/s10620-015-3858-7. 2 Cash BD, Epstein MS, Shah SM. Patient satisfaction with IBS symptom relief using a novel peppermint oil delivery system in a randomized clinical trial and in the general population. Int J Dig Dis. 2016;2(2):1-5. doi:10.4172/2472-1891.100027. 3 Epstein M, Shah S. 4 week results from a US-based, single-arm study to evaluate a novel L-menthol and peppermint oil formulation with a targeted delivery system: Results from the IBSRRET* trial. In: AMERICAN GASTROENTEROLOGICAL ASSOCIATION’S (AGA) FRESTON CONFERENCE - Chicago Illinois. ; 2015. 4 Pubmed.gov search for term "microbiome" - results by year. *Among primary care physicians with a certification in sleep disorders who recommended a brand of modified release melatonin. Quintiles IMS ProVoice July-Sept. 2017 survey.